Login to Your Account



Theravectys Gets $9M for Therapeutic HIV Vaccine

By Cormac Sheridan
Staff Writer

Wednesday, September 5, 2012
Theravectys SAS raised €7.48 million (US$9.4 million) in a third funding round to support what it claims will be the world's first trial of a therapeutic HIV vaccine based on a lentiviral vector.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription